Antisense modulation of Toll-like receptor 4 expression

Source: Expert Opinion on Therapeutic Patents, Volume 13, Number 12, 1 December 2003 , pp. 1887-1889(3)

Publisher: Informa Healthcare

Buy & download fulltext article:


Price: $113.00 plus tax (Refund Policy)


A strategy to decrease the expression of Toll-like receptor 4 (TLR4) using antisense oligonucleotides is claimed. TLR4 has been implicated in sepsis syndrome and in chronic inflammatory diseases such as inflammatory bowel disease. Limiting TLR4 expression by the strategy described in the claim may therefore have clinical utility in these diseases.

Keywords: Toll-like receptor; antisense to Toll-like receptor 4; autoimmune diseases; inflammation; sepsis

Document Type: Miscellaneous

Publication date: December 1, 2003

More about this publication?
Related content


Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page